MedPath
Found 6 clinical trials|View Analysis
Sort by:

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2
Not yet recruiting
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
T Acute Lymphoblastic Leukemia
Interventions
Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Procedure: Bone Marrow Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Biological: Filgrastim
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT06738368
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

Phase 2
Not yet recruiting
Conditions
Enteropathy Associated T Cell Lymphoma
Interventions
Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
Drug: Golidocitinib
First Posted Date
2024-11-22
Last Posted Date
2024-11-22
Lead Sponsor
Ruijin Hospital
Target Recruit Count
7
Registration Number
NCT06701344

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1
Recruiting
Conditions
AIDS-Related Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Interventions
First Posted Date
2017-07-18
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
54
Registration Number
NCT03220022
Locations
🇺🇸

University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

and more 18 locations

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2
Completed
Conditions
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Interventions
First Posted Date
2017-01-18
Last Posted Date
2022-07-13
Lead Sponsor
University of Washington
Target Recruit Count
54
Registration Number
NCT03023046
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2
Withdrawn
Conditions
Recurrent T Lymphoblastic Leukemia/Lymphoma
B Lymphoblastic Lymphoma
Recurrent B Lymphoblastic Lymphoma
Refractory T Lymphoblastic Lymphoma
T Lymphoblastic Lymphoma
B Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2015-09-02
Last Posted Date
2018-11-14
Lead Sponsor
University of Washington
Registration Number
NCT02538926
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

Phase 3
Active, not recruiting
Conditions
Retinal Neoplasm
Retinoblastoma
Interventions
Procedure: Enucleation
Drug: Vincristine, Carboplatin
Radiation: External Beam Radiation
Procedure: Focal Therapies
Drug: vincristine, cyclophosphamide, and doxorubicin
Drug: Vincristine, Carboplatin and Etoposide
Drug: Vincristine and Topotecan
Drug: Vincristine + Carboplatin + Etoposide
Procedure: Periocular carboplatin
Other: G-CSF
First Posted Date
2005-09-16
Last Posted Date
2024-10-09
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
107
Registration Number
NCT00186888
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath